Laboratory of Pathophysiology and Free Radicals, Department of General Pathology-Center of Biological Sciences, State University of Londrina, 86051-990 Londrina, Brazil.
Anticancer Res. 2013 Feb;33(2):737-42.
Transforming growth factor beta-1 (TGF-β1) participation in breast cancer development and metastasis is well-established, however, the clinical meaning of its circulating levels in women with breast cancer is poorly understood.
To characterize the levels of TGF-β1 in plasma from women with breast cancer and to associate them with the main clinical factors associated with disease prognosis.
TGF-β1 levels were measured by Enzyme-linked immunoassay (ELISA). Clinicopathological data were also assessed.
Women bearing triple-negative tumors presented significantly reduced levels of this cytokine when compared to the other subtypes (p=0.0338). Patients with metastases exhibited lower levels of TGF-β1 than the non-metastatic cohort (p=0.0442). Patients with early-onset disease had the highest plasma TGF-β1 levels (p=0.0036). Doxorubicin chemotherapy induced a reduction in TGF-β1 level, promptly after drug infusion (p=0.0494). Patients with TGF-β1 levels lower than 20 pg/ml exhibited a tendency to have a reduced overall survival in a 40-month follow-up.
Lower levels of circulating TGF-β1 are associated with a poor disease prognosis.
转化生长因子-β1（TGF-β1）参与乳腺癌的发生和转移已得到充分证实，然而，其在乳腺癌女性患者循环水平的临床意义仍知之甚少。
描述乳腺癌女性患者血浆中 TGF-β1 的水平，并将其与与疾病预后相关的主要临床因素相关联。
采用酶联免疫吸附试验（ELISA）测量 TGF-β1 水平。还评估了临床病理数据。
与其他亚型相比，三阴性肿瘤患者的这种细胞因子水平显著降低（p=0.0338）。有转移的患者 TGF-β1 水平低于无转移组（p=0.0442）。发病早的患者血浆 TGF-β1 水平最高（p=0.0036）。阿霉素化疗后 TGF-β1 水平降低，在药物输注后即刻（p=0.0494）。在 40 个月的随访中，TGF-β1 水平低于 20pg/ml 的患者总生存率有降低的趋势。
较低的循环 TGF-β1 水平与不良的疾病预后相关。
